CD42a antibody (Middle Region)

Catalog No. ABIN7879522

The Rabbit Polyclonal anti-CD42a antibody (ABIN7879522) specifically detects CD42a in WB and IHC. The antibody is reactive with Human and Mouse samples.

Quick Overview for CD42a antibody (Middle Region) (ABIN7879522)

Target: CD42a (GP9) (Glycoprotein IX (Platelet) (GP9))

Reactivity: Human, Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This CD42a antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC)

Product Details anti-CD42a Antibody

Binding Specificity: Middle Region

Purpose: Glycoprotein 9 Antibody / Gp9 / CD42a

Purification: Immunogen affinity purified

Immunogen: A synthetic peptide corresponding to a sequence in the middle region of human CD42a/GP9 was used as the immunogen for the Glycoprotein 9 antibody.

Isotype: IgG

Application Details

Application Notes: Optimal dilution of the Glycoprotein 9 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Adding 0.2 mL of distilled water will yield a concentration of 500 μg/mL

Buffer: Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4.

Storage: 4 °C,-20 °C

Storage Comment: After reconstitution, the Glycoprotein 9 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.

Target Details for CD42a

Target: CD42a (GP9) (Glycoprotein IX (Platelet) (GP9))

Alternative Name: Glycoprotein 9

Background: Glycoprotein 9 antibody detects Platelet glycoprotein IX, a membrane glycoprotein that forms part of the GPIb-IX-V complex essential for platelet adhesion and thrombus formation. Glycoprotein 9 functions as a structural subunit that stabilizes the GPIbalpha receptor, enabling platelet interaction with von Willebrand factor under high shear conditions. The Glycoprotein 9 antibody is widely used in hematology and cardiovascular research to study platelet function, coagulation, and bleeding disorders.

The protein is encoded by the GP9 gene on human chromosome 3q21.3. Glycoprotein 9 is approximately 177 amino acids long and contains a single leucine-rich repeat flanked by cysteine-rich regions, which maintain receptor conformation and complex assembly. It is expressed exclusively on platelet membranes and megakaryocytes, where it associates non-covalently with GPIbalpha and GPIbbeta to form the functional receptor complex for von Willebrand factor binding.

The Glycoprotein 9 antibody detects a 25 kilodalton band by western blot and shows strong membrane staining in platelets. The GPIb-IX-V complex mediates platelet tethering to exposed subendothelial matrix at sites of vascular injury, initiating platelet activation and aggregation. Defects or mutations in Glycoprotein 9 lead to Bernard-Soulier syndrome, characterized by thrombocytopenia, giant platelets, and impaired adhesion.

Beyond hemostasis, the GPIb-IX-V complex participates in inflammatory and immune signaling. Platelet Glycoprotein 9 contributes to leukocyte recruitment, vascular permeability, and thromboinflammatory responses. Overexpression or dysregulation has been associated with thrombosis and cardiovascular disease, making it an important target for antithrombotic therapy.

Because of its role in platelet adhesion and vascular integrity, Glycoprotein 9 is a critical biomarker for platelet-related disorders. NSJ Bioreagents provides a validated Glycoprotein 9 antibody optimized for its applications, supporting research into hemostasis, thrombosis, and vascular inflammation.

UniProt: P14770